PAQ Therapeutics to Present First Clinical Data for PT0253, a Selective KRAS G12D Degrader, in Late-Breaking Oral Presentation at the 2026 EORTC-NCI-AACR Symposium

Barchart · 2d ago

Presentation to highlight the initial safety profile and antitumor activity of PT0253 in advanced solid tumors, including in patients who received prior (K)RAS-targeted therapy

Read more at prnewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.